Century Therapeutics (IPSC) Asset Writedowns and Impairment (2023 - 2025)

Century Therapeutics (IPSC) has 3 years of Asset Writedowns and Impairment data on file, last reported at $6.8 million in Q3 2025.

• Asset Writedowns and Impairment for Q3 2025 came in at $6.8 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $11.1 million (down 8.69% YoY), and the FY2025 annual result was $6.8 million, up 56.3% from the prior year.
• Asset Writedowns and Impairment improved to $6.8 million in Q3 2025 per IPSC's latest filing, from $4.3 million in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $12.1 million in Q4 2023 and troughed at $4.2 million in Q2 2023.
• A 3-year average of $6.9 million and a median of $5.5 million in 2024 frame the typical range for Asset Writedowns and Impairment.
• On a YoY basis, Asset Writedowns and Impairment climbed as much as 64.37% in 2024 and fell as far as 64.37% in 2024.
• A 3-year view of Asset Writedowns and Impairment shows it stood at $12.1 million in 2023, then tumbled by 64.37% to $4.3 million in 2024, then jumped by 56.3% to $6.8 million in 2025.
• Business Quant data shows IPSC's Asset Writedowns and Impairment at $6.8 million in Q3 2025, $4.3 million in Q4 2024, and $12.1 million in Q4 2023.